# Myriad Genetics Inc: financial statements, quarterly

MYGN · Nasdaq · CIK 899923 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mygn.md) · [Financials](/companies/mygn/financials.md) · [Filings](/companies/mygn/filings.md) · [Insiders](/companies/mygn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mygn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [192](/filings/0000899923-24-000057.md) | [197 d](/filings/0000899923-26-000018.md) | [202](/filings/0000899923-25-000048.md) | [212](/filings/0000899923-25-000086.md) | [213](/filings/0000899923-25-000112.md) | [211 d](/filings/0000899923-26-000018.md) | [196](/filings/0000899923-26-000038.md) | [213](/filings/0000899923-26-000072.md) | [206](/filings/0000899923-25-000112.md) | [210 d](/filings/0000899923-26-000018.md) | [200](/filings/0000899923-26-000038.md) | [191](/filings/0000899923-26-000072.md) |
| Cost of revenue | $m | [57.6](/filings/0000899923-24-000057.md) | [61.6 d](/filings/0000899923-26-000018.md) | [64.6](/filings/0000899923-25-000048.md) | [64.4](/filings/0000899923-25-000086.md) | [63.5](/filings/0000899923-25-000112.md) | [59.7 d](/filings/0000899923-26-000018.md) | [61.7](/filings/0000899923-26-000038.md) | [61.3](/filings/0000899923-26-000072.md) | [61.9](/filings/0000899923-25-000112.md) | [63.0 d](/filings/0000899923-26-000018.md) | [62.8](/filings/0000899923-26-000038.md) | [63.7](/filings/0000899923-26-000072.md) |
| Gross profit | $m | not reported | not reported | [138](/filings/0000899923-25-000048.md) | [147](/filings/0000899923-25-000086.md) | [150](/filings/0000899923-25-000112.md) | [151 d](/filings/0000899923-26-000018.md) | [134](/filings/0000899923-26-000038.md) | [152](/filings/0000899923-26-000072.md) | [144](/filings/0000899923-25-000112.md) | [147 d](/filings/0000899923-26-000018.md) | [138](/filings/0000899923-26-000038.md) | [127](/filings/0000899923-26-000072.md) |
| Research and development | $m | [24.0](/filings/0000899923-24-000057.md) | [21.0 d](/filings/0000899923-26-000018.md) | [24.9](/filings/0000899923-25-000048.md) | [27.1](/filings/0000899923-25-000086.md) | [28.5](/filings/0000899923-25-000112.md) | [32.2 d](/filings/0000899923-26-000018.md) | [27.5](/filings/0000899923-26-000038.md) | [25.6](/filings/0000899923-26-000072.md) | [28.2](/filings/0000899923-25-000112.md) | [25.5 d](/filings/0000899923-26-000018.md) | [27.1](/filings/0000899923-26-000038.md) | [25.0](/filings/0000899923-26-000072.md) |
| Selling, general and administrative | $m | [136](/filings/0000899923-24-000057.md) | [144 d](/filings/0000899923-24-000018.md) | [141](/filings/0000899923-24-000026.md) | [145](/filings/0000899923-24-000041.md) | [139](/filings/0000899923-24-000057.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(60.1)](/filings/0000899923-24-000057.md) | [(31.4) d](/filings/0000899923-26-000018.md) | [(27.9)](/filings/0000899923-25-000048.md) | [(36.5)](/filings/0000899923-25-000086.md) | [(20.0)](/filings/0000899923-25-000112.md) | [(39.0) d](/filings/0000899923-26-000018.md) | [(29.0)](/filings/0000899923-26-000038.md) | [(329)](/filings/0000899923-26-000072.md) | [(23.3)](/filings/0000899923-25-000112.md) | [(5.7) d](/filings/0000899923-26-000018.md) | [(30.7)](/filings/0000899923-26-000038.md) | [(38.9)](/filings/0000899923-26-000072.md) |
| Interest expense | $m | [1.0](/filings/0000899923-23-000087.md) | [0.9 d](/filings/0000899923-24-000018.md) | [0.5](/filings/0000899923-24-000026.md) | [0.8](/filings/0000899923-25-000086.md) | [0.8](/filings/0000899923-25-000112.md) | [0.7 d](/filings/0000899923-26-000018.md) | [0.8](/filings/0000899923-26-000038.md) | [1.5](/filings/0000899923-26-000072.md) | [3.8](/filings/0000899923-25-000112.md) | [4.4 d](/filings/0000899923-26-000018.md) | [4.1](/filings/0000899923-26-000038.md) | [4.1](/filings/0000899923-26-000072.md) |
| Income tax | $m | [0.1](/filings/0000899923-24-000057.md) | [(1.1) d](/filings/0000899923-26-000018.md) | [0.1](/filings/0000899923-25-000048.md) | [(0.5)](/filings/0000899923-25-000086.md) | [0.9](/filings/0000899923-25-000112.md) | [3.4 d](/filings/0000899923-26-000018.md) | [(29.3)](/filings/0000899923-26-000038.md) | [(0.1)](/filings/0000899923-26-000072.md) | [1.2](/filings/0000899923-25-000112.md) | [(1.0) d](/filings/0000899923-26-000018.md) | [0.0](/filings/0000899923-26-000038.md) | [0.6](/filings/0000899923-26-000072.md) |
| Net income | $m | [(61.3)](/filings/0000899923-24-000057.md) | [(31.2) d](/filings/0000899923-26-000018.md) | [(26.0)](/filings/0000899923-25-000112.md) | [(36.7)](/filings/0000899923-25-000112.md) | [(22.1)](/filings/0000899923-25-000112.md) | [(42.5) d](/filings/0000899923-26-000018.md) | [(0.1)](/filings/0000899923-26-000072.md) | [(331)](/filings/0000899923-26-000072.md) | [(27.4)](/filings/0000899923-25-000112.md) | [(7.9) d](/filings/0000899923-26-000018.md) | [(34.1)](/filings/0000899923-26-000072.md) | [(43.2)](/filings/0000899923-26-000072.md) |
| Diluted EPS | $ per share | [(0.75)](/filings/0000899923-24-000057.md) | not reported | [(0.29)](/filings/0000899923-25-000048.md) | [(0.41)](/filings/0000899923-25-000086.md) | [(0.24)](/filings/0000899923-25-000112.md) | not reported | [0.00](/filings/0000899923-26-000038.md) | [(3.57)](/filings/0000899923-26-000072.md) | [(0.29)](/filings/0000899923-25-000112.md) | not reported | [(0.36)](/filings/0000899923-26-000038.md) | [(0.46)](/filings/0000899923-26-000072.md) |
| Basic EPS | $ per share | [(0.75)](/filings/0000899923-24-000057.md) | not reported | [(0.29)](/filings/0000899923-25-000048.md) | [(0.41)](/filings/0000899923-25-000086.md) | [(0.24)](/filings/0000899923-25-000112.md) | not reported | [0.00](/filings/0000899923-26-000038.md) | [(3.57)](/filings/0000899923-26-000072.md) | [(0.29)](/filings/0000899923-25-000112.md) | not reported | [(0.36)](/filings/0000899923-26-000038.md) | [(0.46)](/filings/0000899923-26-000072.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.0](/filings/0000899923-24-000057.md) | [132](/filings/0000899923-26-000018.md) | [96.9](/filings/0000899923-25-000048.md) | [92.4](/filings/0000899923-25-000086.md) | [99.9](/filings/0000899923-25-000112.md) | [102](/filings/0000899923-26-000018.md) | [91.8](/filings/0000899923-26-000038.md) | [74.4](/filings/0000899923-26-000072.md) | [145](/filings/0000899923-25-000112.md) | [150](/filings/0000899923-26-000072.md) | [124](/filings/0000899923-26-000038.md) | [115](/filings/0000899923-26-000072.md) |
| Current assets | $m | [265](/filings/0000899923-23-000087.md) | [314](/filings/0000899923-25-000019.md) | [290](/filings/0000899923-24-000026.md) | [292](/filings/0000899923-24-000041.md) | [293](/filings/0000899923-24-000057.md) | [298](/filings/0000899923-26-000018.md) | [287](/filings/0000899923-25-000048.md) | [284](/filings/0000899923-25-000086.md) | [345](/filings/0000899923-25-000112.md) | [333](/filings/0000899923-26-000072.md) | [313](/filings/0000899923-26-000038.md) | [289](/filings/0000899923-26-000072.md) |
| Total assets | $m | [1,149](/filings/0000899923-23-000087.md) | [1,147](/filings/0000899923-25-000019.md) | [1,111](/filings/0000899923-24-000026.md) | [1,085](/filings/0000899923-24-000041.md) | [1,081](/filings/0000899923-24-000057.md) | [1,028](/filings/0000899923-26-000018.md) | [1,006](/filings/0000899923-25-000048.md) | [677](/filings/0000899923-25-000086.md) | [728](/filings/0000899923-25-000112.md) | [707](/filings/0000899923-26-000072.md) | [674](/filings/0000899923-26-000038.md) | [639](/filings/0000899923-26-000072.md) |
| Current liabilities | $m | [209](/filings/0000899923-23-000087.md) | [156](/filings/0000899923-25-000019.md) | [146](/filings/0000899923-24-000026.md) | [149](/filings/0000899923-24-000041.md) | [154](/filings/0000899923-24-000057.md) | [164](/filings/0000899923-26-000018.md) | [151](/filings/0000899923-25-000048.md) | [200](/filings/0000899923-25-000086.md) | [148](/filings/0000899923-25-000112.md) | [134](/filings/0000899923-26-000072.md) | [130](/filings/0000899923-26-000038.md) | [131](/filings/0000899923-26-000072.md) |
| Total liabilities | $m | [466](/filings/0000899923-23-000087.md) | [363](/filings/0000899923-25-000019.md) | [351](/filings/0000899923-24-000026.md) | [345](/filings/0000899923-24-000041.md) | [350](/filings/0000899923-24-000057.md) | [327](/filings/0000899923-26-000018.md) | [301](/filings/0000899923-25-000048.md) | [289](/filings/0000899923-25-000086.md) | [355](/filings/0000899923-25-000112.md) | [339](/filings/0000899923-26-000072.md) | [336](/filings/0000899923-26-000038.md) | [335](/filings/0000899923-26-000072.md) |
| Long-term debt | $m | [38.5](/filings/0000899923-23-000087.md) | [38.5](/filings/0000899923-25-000019.md) | [38.7](/filings/0000899923-24-000026.md) | [38.8](/filings/0000899923-24-000041.md) | [39.0](/filings/0000899923-24-000057.md) | [39.6](/filings/0000899923-26-000018.md) | [59.3](/filings/0000899923-25-000048.md) | [0.0](/filings/0000899923-25-000086.md) | [120](/filings/0000899923-25-000112.md) | [120](/filings/0000899923-26-000072.md) | [120](/filings/0000899923-26-000038.md) | [121](/filings/0000899923-26-000072.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0000899923-25-000086.md) | not reported | [59.4](/filings/0000899923-25-000086.md) | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [683](/filings/0000899923-24-000057.md) | [783](/filings/0000899923-26-000018.md) | [760](/filings/0000899923-25-000112.md) | [741](/filings/0000899923-25-000112.md) | [732](/filings/0000899923-25-000112.md) | [701](/filings/0000899923-26-000072.md) | [705](/filings/0000899923-26-000072.md) | [388](/filings/0000899923-26-000072.md) | [373](/filings/0000899923-25-000112.md) | [368](/filings/0000899923-26-000072.md) | [337](/filings/0000899923-26-000072.md) | [304](/filings/0000899923-26-000072.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.1) d](/filings/0000899923-24-000057.md) | [(54.7) d](/filings/0000899923-26-000018.md) | [(18.6)](/filings/0000899923-25-000048.md) | [2.6 d](/filings/0000899923-25-000086.md) | [0.7 d](/filings/0000899923-25-000112.md) | [6.6 d](/filings/0000899923-26-000018.md) | [(16.3)](/filings/0000899923-26-000038.md) | [(13.6) d](/filings/0000899923-26-000072.md) | [21.1 d](/filings/0000899923-25-000112.md) | [10.6 d](/filings/0000899923-26-000018.md) | [(15.7)](/filings/0000899923-26-000038.md) | [(8.3) d](/filings/0000899923-26-000072.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [80.7](/filings/0000899923-23-000087.md) | [81.3](/filings/0000899923-24-000026.md) | [81.7](/filings/0000899923-24-000041.md) | [81.9](/filings/0000899923-24-000057.md) | [89.9](/filings/0000899923-25-000048.md) | [90.6](/filings/0000899923-25-000086.md) | [90.9](/filings/0000899923-25-000112.md) | [91.4](/filings/0000899923-26-000038.md) | [92.5](/filings/0000899923-26-000072.md) | [93.1](/filings/0000899923-25-000112.md) | [93.7](/filings/0000899923-26-000038.md) | [94.8](/filings/0000899923-26-000072.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 95,649,645 at 2026-07-28, from the cover of the [10-Q filed 2026-07-31](/filings/0000899923-26-000072.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.